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Abstract
It was investigated whether inhaled budesonide reduces lung volumes in a group of asthmatic children with lung hyperinflation.
Budesonide (800 mg bid, for 2 months) was administered to 12 asthmatic children (mean age, 11.293.3 years) with lung
hyperinflation (TGV]130% predicted and:or RV]140% predicted) in a randomised, placebo controlled, double blind, crossover
study. Body plethysmography (panting frequency controlled at 1·s1) was performed at the beginning, 2 months afterwards
(before crossover) and at the end of the study. Budesonide significantly reduced TGV (2.3590.90 l BTPS or 126924% predicted)
compared with placebo (2.5491.08 l BTPS, P0.014 or 140921% predicted, PB0.05). In addition, budesonide significantly
increased mean specific conductance (0.0690.02 cm H2O1 l s1 to 0.0790.01 cm H2O1 l s1, PB0.05). It was concluded
that budesonide reduced lung hyperinflation most likely by decreasing airway inflammation. © 1999 Elsevier Science Ireland Ltd.
All rights reserved.
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1. Introduction
In a clinical context, hyperinflation implies an abnor-
mal increase in the volume of gas in the lungs at the
end of tidal expiration [1]. However, when it was at-
tempted to relate hyperinflation with the airway nar-
rowing occurring in asthma, the picture is much less
defined as suggested in a recent review [2] which states
that, in this context, there is no clear definition of
hyperinflation and of its underlying mechanisms. The
authors suggest that both altered properties of airways
and lung parenchyma are involved in the development
of hyperinflation and point to the importance of mea-
suring residual volume (RV), thoracic gas volume
(TVG) and total lung capacity (TLC) to understand the
underlying pathophysiological mechanisms.
During an acute attack of asthma [3] there is an
increase in all lung volumes which is due not only to
the expiratory flow limitation but also to the persistent
inspiratory muscle contraction throughout expiration,
caused by a reflex mechanism from the constricted
airways, which increases end-expiratory volume and
produces hyperinflation [4–7]. On the other hand,
chronic increases of functional residual capacity (FRC),
RV and occasionally of TLC can be observed in some
asthmatic patients away from the exacerbations of
asthma [2,8] but the mechanisms responsible for these
changes, such as loss of bronchial-to-parenchyma inter-
dependence, are still under discussion. A prior study
performed in seven asthmatic patients, found a decrease
in FRC after a week of systemic steroids that was
attributed to an improvement of lung elastic recoil [9]
as was later demonstrated [10].
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Although it is accepted that the treatment with
steroids reduces inflammation both in the airways and
in the parenchyma [11,12], the authors were not aware
of any study relating such treatment with measurements
of lung volumes that are dependent, amongst other
factors, upon lung elastic recoil. In order to do that, an
inhaled steroid was given to a group of hyperinflated
asthmatic children and lung volumes were monitored in
a controlled study.
2. Material and methods
2.1. Study subjects
Patients were selected from all asthmatics that have
performed lung function tests in an Allergy Clinic
during 1 year. From these, 13 children with asthma and
lung hyperinflation, aged 6–18 years old were included.
The diagnosis of asthma was made according to ac-
cepted criteria [13]. All patients were free from inhaled
and systemic steroids and from an exacerbation of
asthma for at least 6 weeks before the beginning of the
study. During the study period all patients were only
taking inhaled budesonide regularly and a short-acting
b2 agonist in a prn basis.
According to their clinical symptoms and:or to daily
medication required, 11 patients were classified as hav-
ing moderate persistent asthma, whereas two were la-
belled as mild persistent [14]. Symptoms of asthma were
detected for the first time, in average, since 8.594.2
years ago, with a range between 3.1 and 17.3 years.
Chronic lung hyperinflation was considered whenever
TGV was repeatedly (in three different occasions dur-
ing the previous year) equal or higher than 130%
predicted [15] and:or RV was equal or higher than
140% predicted [16]. The predicted values were calcu-
lated from Zapletal equations [17].
2.2. Study design
The study was performed in two phases (Phase 1 and
Phase 2), with a duration of 4 months. It was a
controlled study, double blind, against placebo accord-
ing to randomisation in two groups (G1 and G2) of six
patients each. A crossover was done at the end of Phase
1. Budesonide (400 mg dose1) or placebo was adminis-
tered to each patient through a Turbohaler® device
twice a day. The content of the inhaler was blinded
both to patients and investigators. Lung volumes were
measured three times during the study — before start-
ing budesonide (day 0), at crossover (day 57) and at the
end of the study (day 113). Patients were instructed to
avoid taking b2 agonists during the 12-h period preced-
ing the lung function measurements. An informed con-
sent was obtained from the tutors in every case and the
study was approved by the Hospital Ethics Committee.
2.3. Methods
A body plethysmograph MasterLab Jaeger
(Wu¨rzburg, Germany) was used to measure lung vol-
umes (TGV, RV and TLC) and specific conductance
(sGaw) according to the method described by Ref. [18].
The procedure followed during measurements was that
recommended by the European Respiratory Society
[19]. Nevertheless, panting frequency was settled at 1
Hz, using a tachometer as a biofeedback signal to the
patient, because lung volumes measured by body
plethysmography with high panting frequencies are
overestimated in asthma [20,21].
2.4. Analysis
The key questions addressed in this study were: did
budesonide modify lung volumes (TGV, RV and TLC)
and sGaw, compared with placebo? Did lung volumes
correlate with airway calibre before and after treatment
with budesonide?
Analysis of variance was used to evaluate the effects
of budesonide and placebo according to the methods
described in Ref. [22]. Each analysis was tested for
period effect and for the presence of carry-over. Delta
lung volumes (lung volumes after budesonide — lung




Distribution by age and sex of the children included
in this study is shown on Table 1. One of the patients
was excluded because he had an asthma attack treated
with oral steroids during placebo phase. For this
reason only 12 patients concluded the study. This group
had the following mean baseline volumes (Table 2):
TGV, 2.791.10 l (141921% pred.); RV, 1.5990.80 l
(170953% pred.); and TLC, 4.5291.62 l (118913%
pred.).
3.2. Effect of budesonide on lung 6olumes
When compared with placebo, only TGV was signifi-
cantly reduced (PB0.05) after 2 months of inhaled
budesonide, from 2.5491.08 to 2.3591.08 l. There
were no differences between basal volumes and volumes
after placebo (Fig. 1).
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3.3. Effect of budesonide on airway calibre
As patients were evaluated through body plethysmog-
raphy, only resistance (or its reciprocal-conductance)
was measured. Specific conductance (sGaw) after 2
months of budesonide increased significantly (PB0.05)
when compared with sGaw after placebo (from 0.069
0.02 to 0.0790.01 cm H2O1·1·s1, Fig. 1). This
increase corresponds to a 17% variation.
3.4. Relation between lung 6olumes and airway calibre
Delta TGV (as defined in Section 2) was significantly
correlated with delta Gaw (r 0.78, PB0.005, Fig. 2).
4. Discussion
With this study it has been shown, in a group of 12
young asthmatics with lung hyperinflation, that TGV
but not RV or TLC decreased significantly after treat-
ment with an inhaled steroid. This was shown through
a double blind, placebo controlled, crossover design.
The reduction of TGV after treatment with budes-
onide implies that the anti-inflammatory medication
reduced end-expiratory volume. Based on the inflamma-
tory theory of asthma, it was hypothesised that this was
due, not only to an increase in airway calibre [23–25],
but also to a reduction in peribronchial and alveolar
inflammation [26] which, when present, causes
Table 1
Characteristics of the asthmatic children with lung hyperinflation studieda
Age SexNo. TGV RV TLC
% Pred l % Predl % Pred l
1.36 144 3.93 105F 2.221 12011
1246.742442.841632 4.40M15
1.03 142 3.42 118M 1.873 1338
13 F 3.64 1814 2.47 243 5.31 130
1164.691681.561275 2.51M10
10 M 2.68 1466 0.97 110 1023.83
1.26 161 3.64 1207 8 F 1.92 129
0.96 146 3.01 1198 7 M 1.60 130
3.171774.78 272 147M 7.999 18
1170.88122 2.651471.35F910
0.991322.17M 1221111 3.36 99
5.7014 114M 3.22 131 1.58 14612
12 170 4.52 1189M:4F 2.70 141Mean 1.59
533 1.62 13– 1.10 21 0.80S.D.
a M, male; F, female; % Pred, % predicted values; S.D., standard deviation.
Table 2
sGaw evolution of asthmatic children with lung hyperinflation during the study
a
Basal After budesonideNo. After placebo
% Predcm H2O
1 l s1 % Pred cm H2O
1 l s1 % Pred cm H2O
1 l s1
90 900.0821 740.082 0.067
2 1230.0761080.067480.03
0.081630.076 68500.063
0.047 564 0.0620.028 7433
0.079 925 0.0660.041 7748
890.082970.0896 990.091
7 44 0.049 43 0.065 570.05
8 580.08430.059520.072
0.056630.039 90850.0539
10 41 0.028 18 0.06 390.063
0.066 64 0.0511 49 0.059 57
940.0651280.08812 1320.091
79*0.072*670.06065Mean 0.060
0.021 29 0.018S.D. 27 270.012
a % Pred, % predicted values; S.D., standard deviation.
* PB0.05 when compared with post placebo.
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Fig. 1. Comparison of lung volumes (residual volume (RV), upper left panel; thoracic gas volume (TGV), upper right panel; total lung capacity
(TLC), lower left panel) and of specific conductance (sGaw) before budesonide or placebo (basal), after placebo (placebo) and after budesonide
(Bud) treatment of asthmatic children with lung hyperinflation. On the left hand side of each graphic is represented the individual variation. On
the right hand side is represented the mean variation (9standard variation); * PB0.05.
a temporary loss of the relationship between small
bronchi and parenchyma, thus reducing elastic recoil
[27,28]. This is suggested in this study by the fact that a
small improvement in airway calibre after budesonide,
demonstrated by the increase in sGaw, was not accom-
panied by a change in RV, which remained higher and
not different from placebo. This probably means that a
higher RV depends not only on airway calibre but also
on persistent parenchymal changes such as a reduction
in lung elastic recoil that also contributes to the expira-
tory flow limitation. Similar observations were made by
S¸ekerel et al. [8] who found a reduction of TLC after 8
weeks of treatment with budesonide, 400 mg day1.
A recent study [29] has shown that, in chronic stable
asthma, lung volumes assessed by measurements of
TLC, can be larger than predicted at the start of
adolescence and suggested that this change was due to
the mitogenic effect of inflammatory mediators which
stimulated alveolar multiplication during childhood.
This hypothesis is different from a previous one [30]
which explained the hyperinflation in chronic asthmat-
ics by a process of alveolar destruction because of the
stretching caused by the trapped gas. In this regard it is
interesting to note that the younger cases, also at the
beginning of adolescence, had higher baseline values of
TLC than the older patients, a finding which agrees
with the above mentioned hypothesis. The authors are
aware that the measurement of TLC by plethysmogra-
phy can produce methodological errors, however, they
were minimised by a panting frequency B1 Hz. So it
was confirmed, as others, that TLC is increased in some
of these patients with asthma, whether this is caused by
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Fig. 2. Graphic representation of the statistically significant correla-
tion between delta thoracic gas volume (TGV) and delta Gaw (before
and after budesonide) of asthmatic children with lung hyperinflation.
References
[1] G.J. Gibson, Pulmonary hyperinflation: a clinical overview, Eur.
Respir. J. 9 (1996) 2640–2649.
[2] R. Pellegrino, V. Brusasco, On the causes of lung hyperinflation
during bronchoconstriction, Eur. Respir. J. 10 (1997) 468–475.
[3] A.J. Woolcock, J. Read, Lung volumes in exacerbations of
asthma, Am. J. Med. 41 (1966) 259–273.
[4] J. Martin, E. Powell, S. Shore, J. Emrich, L.A. Engel, The role
of respiratory muscles in the hyperinflation of bronchial asthma,
Am. Rev. Respir. Dis. 121 (1980) 441–447.
[5] N. Mu¨ller, A.C. Bryan, N. Zamel, Tonic inspiratory muscle
activity as a cause of hyperinflation in histamine-induced
asthma, J. Appl. Physiol. 49 (1980) 869–874.
[6] R. Pellegrino, B. Violante, S. Nava, C. Rampulla, V. Brusasco,
J.R. Rodarte, Relationship between expiratory airflow limitation
and hyperinflation during methacholine-induced bronchocon-
striction, J. Appl. Physiol. 75 (1993a) 1720–1727.
[7] P.W. Collet, T. Brancatisano, L.A. Engel, Changes in the glottic
aperture during bronchial asthma, Am. Rev. Respir. Dis. 128
(1983) 719–723.
[8] B.E. S¸ekerel, A. Tuncer, Y. Sarac¸lar, G. Adaliulu, Inhaled
budesonide reduces lung hyperinflation in children with asthma,
Acta Paediatr. 86 (1997) 932–936.
[9] W.M. Gold, H.S. Kaufman, J.A. Nadel, Elastic recoil of the
lungs in chronic asthmatic patients before and after therapy, J.
Appl. Physiol. 23 (1967) 433–438.
[10] A.J. Woolkock, J. Read, The static elastic properties of the lungs
in asthma, Am. Rev. Respir. Dis. 98 (1968) 788–794.
[11] S. Pedersen, Can steroids cause asthma to remit? Am. J. Crit.
Care Med. 153 (1996) S31
[12] V. Keatings, A. Jatakanon, Y. Worsdell, P. Barnes, Effects of
inhaled and oral glucocorticoids on inflammatory indices in
asthma and COPD, Am. J. Crit. Care Med. 155 (1997) 542–548.
[13] International Consensus Report on Diagnosis and Treatment of
Asthma, Eur. Respir. J. 5 (1992) 601–641.
[14] National Institutes of Health (NHLBI), Global strategy for
asthma management and prevention. Publication no 95–3659
(1995).
[15] S.P. Blackie, S. Al-Majed, C.A. Staples, C. Hilliam, P.D. Pare´,
Changes in total lung capacity during acute spontaneous asthma,
Am. Rev. Respir. Dis. 142 (1990) 79–83.
[16] B.E. Pennock, J.J. Cottrell, R.M. Rogers, Pulmonary function
testing. What is normal?, Arch. Intern. Med. 143 (1983) 2123–
2127.
[17] Working Group Paediatrics, Standardisation of Lung Function
in Paediatrics. Compilation of reference values for lung function
measurements in children, Eur. Respir. J. 2 (Suppl. 4) (1989)
184–264.
[18] A.B. DuBois, S.Y. Botelho, G.N. Bedell, J.H.J.r. Comroe, A
new method for measuring airway resistance in man using a
body plethysmograph: values in normal subjects and in patients
with respiratory disease, J. Clin. Invest. 35 (1956) 322–326.
[19] Official Statement of the European Respiratory Society, Stan-
dardised Lung Function Testing. Lung volumes and forced
ventilatory flows, Eur. Respir. J. 6 (Suppl. 16) (1993) 5–40.
[20] D.O. Rodenstein, D.C. Stanescu, Frequency dependence of
plethysmograph volume in heathy and asthmatic subjects, J.
Appl. Physiol. 52 (1982) 159–165.
[21] S.A. Shore, O. Huk, S. Mannix, J.G. Martin, Effect of panting
frequency on the pletysmographic determination of thoracic gas
volume in chronic obstructive pulmonary disease, Am. Rev.
Respir. Dis. 128 (1983) 54–59.
[22] D.A. Ratkowsky, M.A. Evans, J.R. Alldredge, Crossover exper-
iments. Design: analysis and application, in: D.A. Ratkoswsky,
M.A. Evans, J.R. Alldredge (Eds.), Statistics: Textbooks and
Monographs, Dekker, New York, 1993, pp. 77–120.
a higher rate of alveolar multiplication or by remod-
elling of lung tissues or both it is not yet clear.
Another explanation for the increase in TLC could
be related to an increase in respiratory muscle strength
in chronic asthmatics due to the persistent tonic activity
of the inspiratory muscle during expiration. Since res-
piratory pressures have not been measured, the involve-
ment of the respiratory muscles on the genesis of
hyperinflation cannot be excluded, although these
changes are considered less likely than those of lung
parenchyma. However, the authors’ research findings
[31], have shown that, at least maximal mouth pressures
are similar in children and adolescents with asthma and
a group of age matched controls.
The results show that an inhaled steroid, budesonide,
can decrease lung volumes in a group of young asth-
matics with lung hyperinflation. This reduction in lung
volumes was closely related with the increase of airway
calibre thus suggesting a major role of airway inflam-
mation in the genesis of chronic lung hyperinflation in
asthma.
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